

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Sung Kee Jo et al. Confirmation No.:  
Serial No. :  
Filed :  
TC/A.U. :  
Examiner :

Docket No. : 03-557  
Customer No. : 34704

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with the requirements of 37 CFR 1.97 and 1.98, Applicants hereby submit the documents listed hereinbelow, copies enclosed.

- (1) Korean Document No. KR 10-2000-0023772 published May 3, 2000. The document is in Korean however an English abstract is provided. This document discloses a crude drug composition prepared by mixing Angelicae gigantis radix, Cnidium officinale Makino and Paeoniae Radix and extracting is provided, which has low toxicity and side effects and may be effectively used for prevention and recovery of various diseases and increase of immunity and hematopoiesis.

The undersigned submits the above-identified references for independent consideration by the Examiner and does not make any admission that these references are or are not material to

the present invention or that these references are or are not prior art with respect to the present invention.

Respectfully submitted,

Sung Kae Jo et al.

By



Gregory P. LaPointe  
Attorney for Applicants


Reg. No.: 28,395

Tel: (203) 777-6628

Fax: (203) 865-0297

Date: August 25, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313" on August 25, 2003.

  
Rachel Piscitelli

+

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible][illegible]

Date Considered

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+